Mobile

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available Therapies

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-017671-22

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To provide eribulin to patients with advanced breast cancer who have no further treatment options and therapy is requested by an investigator

Critère d'inclusion

  • Advanced and/or metastatic breast cancer

Liens